Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implication for future pricing considerations

Isabella Piassi Godói, André Soares Santos, Edna Afonso Reis, Livia Lovato Pires de Lemos, Cristina Mariano Ruas Brandão, Juliana Alvares, Francisco de Assis Acurcio, Brian Godman, Augusto Afonso Guerra Júnior

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market (CMED) for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.
LanguageEnglish
Article number41
Number of pages9
JournalFrontiers in Pharmacology
Volume8
DOIs
Publication statusPublished - 2 Feb 2017

Fingerprint

Dengue Vaccines
Brazil
Vaccines
Dengue
Costs and Cost Analysis
Public Health
Dengue Virus
Equidae
Health Insurance
Information Systems
Population
Appointments and Schedules
Cross-Sectional Studies
Infection
Research
Pharmaceutical Preparations
CYD-TDV vaccine

Keywords

  • dengue
  • willingness to pay
  • vaccine
  • consumers
  • Brazil

Cite this

Godói, I. P., Santos, A. S., Reis, E. A., Lovato Pires de Lemos, L., Brandão, C. M. R., Alvares, J., ... Guerra Júnior, A. A. (2017). Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implication for future pricing considerations. Frontiers in Pharmacology , 8, [41]. https://doi.org/10.3389/fphar.2017.00041
Godói, Isabella Piassi ; Santos, André Soares ; Reis, Edna Afonso ; Lovato Pires de Lemos, Livia ; Brandão, Cristina Mariano Ruas ; Alvares, Juliana ; de Assis Acurcio, Francisco ; Godman, Brian ; Guerra Júnior, Augusto Afonso. / Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil : implication for future pricing considerations. In: Frontiers in Pharmacology . 2017 ; Vol. 8.
@article{4dc45ad843b04deda1061fe8c8ba7b98,
title = "Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia{\circledR}) in Brazil: implication for future pricing considerations",
abstract = "Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4{\%}) had completed high school (62.17{\%}), were working (74.4{\%}), had private health insurance (64.5{\%}) and did not have dengue (67.4{\%}). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market (CMED) for the commercialization of Dengvaxia{\circledR} for three doses, only 17{\%} of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.",
keywords = "dengue, willingness to pay, vaccine, consumers, Brazil",
author = "God{\'o}i, {Isabella Piassi} and Santos, {Andr{\'e} Soares} and Reis, {Edna Afonso} and {Lovato Pires de Lemos}, Livia and Brand{\~a}o, {Cristina Mariano Ruas} and Juliana Alvares and {de Assis Acurcio}, Francisco and Brian Godman and {Guerra J{\'u}nior}, {Augusto Afonso}",
year = "2017",
month = "2",
day = "2",
doi = "10.3389/fphar.2017.00041",
language = "English",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",

}

Godói, IP, Santos, AS, Reis, EA, Lovato Pires de Lemos, L, Brandão, CMR, Alvares, J, de Assis Acurcio, F, Godman, B & Guerra Júnior, AA 2017, 'Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil: implication for future pricing considerations' Frontiers in Pharmacology , vol. 8, 41. https://doi.org/10.3389/fphar.2017.00041

Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil : implication for future pricing considerations. / Godói, Isabella Piassi; Santos, André Soares; Reis, Edna Afonso; Lovato Pires de Lemos, Livia; Brandão, Cristina Mariano Ruas; Alvares, Juliana; de Assis Acurcio, Francisco; Godman, Brian; Guerra Júnior, Augusto Afonso.

In: Frontiers in Pharmacology , Vol. 8, 41, 02.02.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil

T2 - Frontiers in Pharmacology

AU - Godói, Isabella Piassi

AU - Santos, André Soares

AU - Reis, Edna Afonso

AU - Lovato Pires de Lemos, Livia

AU - Brandão, Cristina Mariano Ruas

AU - Alvares, Juliana

AU - de Assis Acurcio, Francisco

AU - Godman, Brian

AU - Guerra Júnior, Augusto Afonso

PY - 2017/2/2

Y1 - 2017/2/2

N2 - Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market (CMED) for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.

AB - Introduction and objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market (CMED) for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.

KW - dengue

KW - willingness to pay

KW - vaccine

KW - consumers

KW - Brazil

UR - http://journal.frontiersin.org/article/10.3389/fphar.2017.00041/abstract

U2 - 10.3389/fphar.2017.00041

DO - 10.3389/fphar.2017.00041

M3 - Article

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 41

ER -